12:00 AM
 | 
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Kineret anakinra: Phase II

In a 419-patient study, 42 percent of patients treated with the combination of 1 mg/kg/day subcutaneous Kineret and methotrexate experienced an...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >